| アブストラクト | INTRODUCTION: Lenalidomide is an immunomodulatory agent with multiple mechanisms of action, and treatment with lenalidomide is associated with adverse events such as thrombosis and abdominal pain; nonetheless, other rarer adverse events do exist, with few knowledge from physicians and pharmacists. For such adverse events, pharmacovigilance databases are of great interest. CASE REPORT: A 71-year-old patient with no rheumatologic history, in complete remission of a mantle-cell lymphoma following rituximab, doxorubicin, vincristine, cyclophosphamide, and prednisone induction, received a maintenance treatment with rituximab and lenalidomide. After each course of lenalidomide and with no other new medication, the patient presented with fever and high inflammatory markers level, and a scapular-belt arthritis. MANAGEMENT AND OUTCOME: The patient was managed with non-steroidal anti-inflammatory drugs and colchicine, with symptomatology and inflammation improvement. After discontinuation of lenalidomide, he had no arthritis relapse; it was then concluded that the patient had a lenalidomide-induced arthritis. We interrogated the national and international (VigiBase(R)) pharmacovigilance databases and found that arthritis in the context of lenalidomide exposure is a rare finding, with only three reported cases in France; 0.13% of adverse events reported with lenalidomide in the international database VigiBase(R) were arthritis. DISCUSSION: Our case then reports an uncommon finding, of which both pharmacists and physicians should be aware due to the wide and increasing use of lenalidomide. |
|---|
| ジャーナル名 | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |
|---|
| Pubmed追加日 | 2021/10/1 |
|---|
| 投稿者 | Icard, Charlotte; Mocquot, Pauline; Nogaro, Jean-Claude; Despas, Fabien; Gauthier, Martin |
|---|
| 組織名 | Department of Medical and Clinic Pharmacology, 36760CHU de Toulouse, France.;Department of Hematology, 54909Institut Universitaire du Cancer-Oncopole, France.;UMR1027, Inserm, 173638Universite Paul Sabatier, France.;Department of Medical and Clinic Pharmacology, Faculte de Medecine,;173638Universite Paul Sabatier, France.;Centre Midi-Pyrenees de Pharmacovigilance, de Pharmacoepidemiologie et;d'Informations sur le Medicament, Centre Hospitalier Universitaire de Toulouse,;France.;INSERM CIC 1436 Toulouse, Centre d'Investigation Clinique de Toulouse, Centre;Hospitalier Universitaire de Toulouse, France.;Centre Hospitalier de Cahors, Cahors, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34590522/ |
|---|
